Any news on advancements in Parkinson's disease treatments or medication

Between 2 November and 3 November 2026, significant updates in Parkinson's research included the launch of a major 80,000-sample biomarker study to identify early molecular indicators of the disease. Additionally, pharmaceutical companies Arvinas and Neurocrine Biosciences provided updates on their treatment pipelines, including new Phase 1 data for the LRRK2 protein degrader ARV-102 and upcoming spotlights on neuropsychiatry breakthroughs.

• Launch of UKB-PRISM biomarker study: On 2 November 2026, Alamar Biosciences and Nightingale Health launched the UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife (UKB-PRISM) study, which will analyze 80,000 blood samples to detect Parkinson's disease biomarkers decades before diagnosis.
• Arvinas ARV-102 Phase 1 update: On 3 November 2026, Arvinas reported corporate updates for ARV-102, an oral PROTAC degrader targeting the LRRK2 protein; recent Phase 1 data demonstrated changes in biomarkers associated with inflammation and nerve cell function in Parkinson's patients. 📅 Calendar file (.ics) Arvinas Q3 Corporate and ARV-102 Update November 3, 2026
• Neurocrine Biosciences pipeline announcement: On 3 November 2026, Neurocrine Biosciences announced it will spotlight its neuropsychiatry and movement disorder pipeline, including breakthroughs in Parkinson's-related research, at the 2026 NEI Fall Congress scheduled for 5–8 November. (November 5, 2026 – November 8, 2026) 📅 Calendar file (.ics) Neurocrine Biosciences at NEI Fall Congress November 5, 2026 – November 8, 2026
• ICER Final Evidence Report summary: On 3 November 2026, a final summary of the Institute for Clinical and Economic Review (ICER) report on Tavapadon (Juvmo) was released, concluding that while the drug effectively manages motor symptoms, its clinical benefits are comparable to existing generic treatments. 📅 Calendar file (.ics) ICER Final Evidence Report Summary for Parkinson's November 3, 2026

On 1 November 2026, significant updates in Parkinson's research included the launch of a Phase 1 clinical trial for NCR201, a novel stem-cell therapy for advanced patients. Additionally, a major UCLA study identified a 2.5-fold increase in disease risk linked to a common pesticide, and the first-in-class medication Tavapadon (Juvmo) began its commercial rollout in the United States.

• Launch of NCR201 stem-cell clinical trial: On 1 November 2026, a Phase 1 clinical trial (NCT06553027) officially began for NCR201, an investigational stem-cell therapy targeting patients with moderate-to-advanced Parkinson's disease who have previously received deep brain stimulation (DBS) treatment. 📅 Calendar file (.ics) NCR201 Stem-Cell Trial Start November 1, 2026
• UCLA study on pesticide risk: A study published on 1 November 2026 by UCLA researchers found that long-term exposure to the pesticide chlorpyrifos is associated with a 2.5-fold increase in Parkinson's disease risk and identified a biological mechanism that could be targeted for protection.
• Commercial availability of Tavapadon (Juvmo): As of 1 November 2026, the newly approved medication Tavapadon (marketed as Juvmo) is officially available for patients in the United States, marking the first commercial release of a selective D1/D5 receptor agonist for Parkinson's.
• Focused ultrasound educational webinar: On 1 November 2026, a major patient education webinar was conducted to provide updates on focused ultrasound, a non-invasive surgical option for managing tremors and motor fluctuations in Parkinson's patients. 📅 Calendar file (.ics) Focused Ultrasound Treatment Webinar November 2, 2026 at 01:30 GMT+2 – November 2, 2026 at 02:30 GMT+2

Between 29 and 30 October 2026, significant advancements in Parkinson's disease treatment were reported, led by the world's first post-approval stem-cell transplant in Japan using iPS cells. Additionally, a new wearable device for hand tremors received clearance, and a major cell therapy developer successfully launched an IPO to fund further clinical testing of its personalized neuron-replacement treatment.

• World's first post-approval stem-cell transplant: On 30 October 2026, Sumitomo Pharma announced that the first patient had undergone a pioneering stem-cell transplant using Amchepry (raguneprocel) at Kyoto University Hospital, following the therapy's conditional approval in Japan. 📅 Calendar file (.ics) First post-approval stem-cell transplant for Parkinson's October 30, 2026
• Aspen Neuroscience IPO for cell therapy: On 29 October 2026, Aspen Neuroscience raised $141 million in its initial public offering to advance 'sasineprocel,' a personalized cell therapy designed to replace lost dopamine-producing neurons, into deeper clinical testing. (October 30, 2026) 📅 Calendar file (.ics) Aspen Neuroscience Wall Street Debut October 30, 2026
• Wearable device cleared for hand tremors: On 30 October 2026, a new wearable device from Cala Health was cleared for treating hand tremors in Parkinson's patients, featuring adaptive calibration to adjust to changes in tremor characteristics throughout the day. 📅 Calendar file (.ics) Clearance of wearable device for Parkinson's tremors October 30, 2026
• AviadoBio gene therapy preclinical data: On 29 October 2026, AviadoBio presented data showing that its investigational gene therapy, AVB-SNCA, achieved up to 80% knockdown of the alpha-synuclein gene in human neurons, supporting its development as a one-time treatment.
• New MRI method for HIFU treatment control: Researchers reported on 29 October 2026 that a new MRI processing method improves the visualization of brain lesions during High-Intensity Focused Ultrasound (HIFU) procedures, optimizing follow-up for Parkinson's patients.

Between 27 and 28 October 2026, significant updates in Parkinson's disease research included the successful application of noninvasive focused ultrasound to ease motor symptoms and the completion of patient enrollment for a novel gut-selective therapy (VT-5006). Additionally, new clinical data for the experimental pill bezisterim showed promise in reducing brain inflammation, and a major study highlighted the effectiveness of specialized inpatient programs in preventing hospital medication errors.

• Noninvasive Focused Ultrasound for motor symptoms: On 27 October 2026, researchers reported that noninvasive focused ultrasound treatment provided immediate relief from tremors and stiffness for Parkinson's patients, offering a non-surgical alternative to deep-brain stimulation.
• Vertero Therapeutics Phase 1b enrollment completion: On 27 October 2026, Vertero Therapeutics announced the completion of patient enrollment for its Phase 1b study of VT-5006, a first-in-class gut-selective molecule designed to slow disease progression, with topline data expected by the end of 2026.
• BioVie Bezisterim Phase 2 trial results: On 28 October 2026, results from the Phase 2 SUNRISE-PD trial indicated that the oral drug bezisterim significantly improved motor and non-motor symptoms in a subgroup of patients with high inflammation markers. 📅 Calendar file (.ics) BioVie Bezisterim Phase 2 Results Presentation October 28, 2026
• Inpatient program reduces medication errors: A study published on 27 October 2026 in Annals of Neurology demonstrated that a dedicated Parkinson’s inpatient program using electronic alerts and expert support significantly reduced hospital medication errors and improved discharge outcomes.